Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Dementia diagnosis recording in general hospitals is increasing but remains less likely in some groups. 1 key finding →

Design: cohort study Participants: 21,387 Evidence: moderate

Our findings suggest that clinicians should consider sedative-associated, hypoxic, and septic delirium, which often co-occur, as distinct indicators of acute brain injury and seek to identify all potential risk factors that may impact on long-term cognitive impairment, especially those that are iatrogenic and potentially modifiable such as sedation. 2 key findings →

Design: cohort study Participants: 1,048 Evidence: moderate

Alzheimer's disease is one of the most heritable diseases in elderly people and the most common type of dementia. 4 key findings →

Design: cohort study Participants: 926 Evidence: moderate

Despite differences in CVR management within the countries considered, it was possible to design and implement the HATICE multidomain intervention. 4 key findings →

Design: randomized controlled trial Evidence: high

Prevalence and Risk Factors for Fecal Incontinence in Home Hospice

✓ Peer-reviewed alzhub usefulness score 70 out of 100. The American journal of hospice & palliative care 2018-06-24

Further studies are needed to identify modifiable risk factors for FI detection and its symptom management in this patient population. 5 key findings →

Design: cohort study Participants: 4,314 Evidence: moderate

This multicenter randomized clinical trial demonstrated the feasibility of sham-surgery-controlled stereotactic gene delivery studies in patients with AD. 3 key findings →

Design: clinical trial Participants: 49 Evidence: high

The mean (SD) age was 73.7 (6.0) years, and the mean (SD) follow-up time was 3.7 (1.2) years. 3 key findings →

Design: longitudinal study Participants: 223 Evidence: moderate

The plush toy used in this study offered marginally greater value for money than PARO in improving agitation. 4 key findings →

Design: randomized controlled trial Participants: 415 Evidence: high

The potential determinants of cognitive decline identified in this study, in particular modifiable risk factors, should be tested in the context of randomised controlled trials. 2 key findings →

Design: longitudinal study Participants: 626 Evidence: high

Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Neurology 2018-01-31

We systematically searched PubMed for eligible studies reporting data on CSF biomarkers reflecting amyloid precursor protein metabolism (Aβ42, Aβ40), neurodegeneration (t-tau), and tangle pathology (p-tau) in symptomatic sporadic CAA cohorts vs controls and patients with Alzheimer disease (AD). 4 key findings →

Design: meta-analysis Participants: 59 Evidence: high

Vitamins and minerals play multiple functions within the central nervous system which may help to maintain brain health and optimal cognitive functioning. 4 key findings →

Participants: 28 Evidence: high

Long-term adherence to the MIND diet was moderately associated with better verbal memory in later life. 2 key findings →

Design: cohort study Participants: 16,058 Evidence: moderate

Technology-based cognitive training and rehabilitation interventions show promise, but the findings were inconsistent due to the variations in study design. 2 key findings →

Design: systematic review Evidence: high

Twelve studies with 195 PwD and four with 53 PwMCI met the inclusion criteria. 5 key findings →

Design: systematic review Evidence: high

CrExp therapy has greater positive effects on cognitive functions and daily living ability than standard cognitive training. 1 key finding →

Participants: 93 Evidence: low

Modifiable lifestyle risk factors have been identified as playing a major role in the development of dementia; hence, interventions addressing these risk factors represent a significant opportunity to reduce the number of people developing dementia. 2 key findings →

Design: randomized controlled trial Evidence: high

Unrecognized Cardiovascular Emergencies Among Medicare Patients

✓ Peer-reviewed alzhub usefulness score 69 out of 100. JAMA internal medicine 2018-04-01

There were 1 561 940 patients, including 17 963 hospitalized for ruptured AAA, 304 980 for AMI, 1 181 648 for stroke, 19 675 for aortic dissection, and 37 674 for SAH. 3 key findings →

Design: cohort study Participants: 940 Evidence: moderate

Quality of life of people with advanced dementia living in nursing homes is often suboptimal. 1 key finding →

Design: randomized controlled trial Evidence: high

Estimating the survival of elderly patients diagnosed with dementia in Taiwan: A longitudinal study

✓ Peer-reviewed alzhub usefulness score 69 out of 100. PloS one 2018-07-25

The survival prediction model demonstrated moderate accuracy for predicting mortality at 6 and 12 months before death in elderly patients with dementia. 2 key findings →

Design: longitudinal study Participants: 37,289 Evidence: moderate

Baseline EDS was associated with increased longitudinal Aβ accumulation in elderly persons without dementia, suggesting that those with EDS may be more vulnerable to pathologic changes associated with Alzheimer disease. 5 key findings →

Design: longitudinal study Participants: 283 Evidence: moderate

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed